The story of ImClone Systems Inc. (NASDAQ: IMCL) in its endeavor to sell itself surely feels by now like a never-ending saga, with twists, derisive comments from management and even a mystery. I guess that with Carl Icahn at the helm it's not surprising; he would always try to get the best price he could.

After Icahn announced nearly a month ago that ImClone has a mystery suitor that would pay $70 a share to Bristol-Myers Squibb (NYSE: BMY)'s offer of $60 a share, today the mystery was unraveled and the suitor revealed. (I must admit I was somewhat skeptical, almost thinking this was some sort of tactic by Icahn to get to BMY, but he was serious.) While Pfizer Inc. (NYSE: PFE) has been the name most tossed around as the likely candidate, another name that's been cited -- Eli Lilly and Co. (NYSE: LLY) -- turned out to be the one.

As it was, after a rival buyer was revealed, Bristol indeed increased its bid for ImClone to $62 per share last week, but since Icahn insisted the unnamed large pharma company was willing to pay much more, he exchanged some very colorful comments with Bristol's chief.

The Wall Street Journal finally reported this afternoon it is Lilly that is in advanced talks to acquire ImClone for about $6.1 billion. There's no doubt Lilly would benefit from ImClone's one and only product, Erbitux -- a lucrative cancer drug. Also, as Lilly sees its drugs come off patent, and with its own poor pipeline of cancer drugs -- not to mention its recent troubles getting new drugs past the FDA -- this acquisition would make sense.

The deal's deadline is tonight. If Lilly indeed issues a formal offer, I bet Icahn hopes Bristol would increase its offer as not only does BMY already own about 17% of ImClone, it also co-markets Erbitux, and is simply seen by many as the natural buyer. I doubt we've seen the last of this story.